급성 신손상(AKI) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 리포트(주요 32 시장), 2025-2035년

Global Acute Kidney Injury (AKI) Market Outlook

Thelansis's "Global Acute Kidney Injury (AKI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Kidney Injury treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Acute Kidney Injury (AKI) Overview

Acute kidney injury (AKI) is a rapid, potentially reversible decline in renal function characterised by abrupt reduction in glomerular filtration rate, azotaemia, and frequently oliguria, classified by KDIGO criteria into three severity stages based on serum creatinine rise and urine output thresholds. The pathophysiology encompasses prerenal - haemodynamic insufficiency from volume depletion, sepsis, or cardiorenal syndrome - intrinsic renal - tubular injury from ischaemia or nephrotoxins, glomerulonephritis, or interstitial nephritis - and postrenal - obstructive uropathy - mechanisms, with acute tubular necrosis representing the most prevalent intrinsic aetiology. Patients present with declining urine output, fluid overload, electrolyte disturbances - hyperkalaemia, metabolic acidosis, hyponatraemia - and uraemic symptoms in severe cases. Diagnosis integrates serum creatinine and urine output trajectory, urinalysis with microscopy, renal ultrasonography, and targeted investigations addressing aetiology - including complement, ANCA, anti-GBM antibodies, and renal biopsy where indicated. Management is predominantly supportive - optimising haemodynamics, eliminating nephrotoxins, managing fluid balance, correcting electrolyte derangements, and addressing the underlying cause; renal replacement therapy is instituted for refractory hyperkalaemia, metabolic acidosis, volume overload, or uraemic complications. Emerging biomarkers - NGAL, KIM-1, and TIMP-2/IGFBP-7 - facilitate earlier AKI detection and risk stratification. Prognosis varies with aetiology and severity; survivors carry elevated risks of chronic kidney disease progression, cardiovascular events, and recurrent AKI, necessitating structured nephrology follow-up and patient-centred long-term renal surveillance.

Key Highlights

• In Germany, incident AKI cases are projected to increase from approximately 152,260 in 2025 to 155,034 by 2035.
• AKI remains a major cause of hospitalization and is associated with significant morbidity, mortality, and healthcare burden.
• Elderly patients and individuals with chronic kidney disease continue to represent high-risk populations.
• Early diagnosis and timely intervention are critical to preventing progression to chronic kidney disease and kidney failure.
• Increasing adoption of biomarker-based monitoring and critical care management is improving patient outcomes.

Market Overview

• The Germany AKI market is projected to grow from approximately $105 MN to $230 MN by 2035.
• Market growth is supported by:
• Rising hospitalization rates and critical care utilization
• Increasing adoption of renal monitoring and supportive therapies
• Market expansion is driven by growing awareness of kidney injury prevention and management.
• Future growth will depend on novel renal protective therapies and early diagnostic technologies.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• M2RLAB SL
• Hope Biosciences LLC
• CalciMedica, Inc.
• AstraZeneca
• Arch Biopartners Inc.
• Novartis Pharmaceuticals
• EnnovaBio
• Bilix Co., Ltd.
• Noorik Biopharmaceuticals AG
• Vantive Health LLC

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)